Valuation: SCYNEXIS, Inc.

Market Cap 43.99M 38.46M 35.34M 32.94M 62.48M 4.19B 63.43M 424M 165M 2.06B 165M 162M 7.09B P/E 2026 *
-1.09x
P/E 2027 * -1.76x
Enterprise Value 43.99M 38.46M 35.34M 32.94M 62.48M 4.19B 63.43M 424M 165M 2.06B 165M 162M 7.09B EV / Sales 2026 *
38.1x
EV / Sales 2027 * 6.59x
Free-Float
98.15%
Yield 2026 *
-
Yield 2027 * -

Last Transcript: SCYNEXIS, Inc.

1 day+4.73%
1 week+15.06%
Current month+8.85%
1 month-9.22%
3 months-37.63%
6 months-13.27%
Current year-12.44%
1 week 3.83
Extreme 3.83
4.74
1 month 3.68
Extreme 3.68
4.81
Current year 3.68
Extreme 3.68
9.12
1 year 3.68
Extreme 3.68
10.48
3 years 3.68
Extreme 3.68
30.96
5 years 3.68
Extreme 3.68
64.8
10 years 3.68
Extreme 3.68
440.8
Manager TitleAgeSince
Chief Executive Officer 61 01/01/2023
Director of Finance/CFO 65 24/10/2022
Chief Tech/Sci/R&D Officer - 01/10/2020
Director TitleAgeSince
Director/Board Member 73 01/12/2008
Chairman 67 04/06/2015
Director/Board Member 61 01/01/2023
Date Insider Type Main position Quantity % Market Cap.
26/06Free

Director

5,750 0.0072%
26/06Free

Chairman

5,750 0.0072%
26/06Free

Director

5,750 0.0072%
Change 5-day change 1-year change 3-year change Capi.($)
+4.73%+15.06%-24.29%-82.19% 43.99M
+1.86%+0.48%+55.50%+163.08% 1,082B
+3.57%+3.29%+68.60%+61.03% 633B
+3.99%+3.05%+37.93%+93.37% 461B
+3.86%+1.64%+31.35%+24.29% 338B
-0.56%+0.96%+39.86%+36.64% 299B
-0.08%+1.30%+30.37%+44.02% 291B
-1.54%+2.81%-27.56%-39.45% 222B
+3.55%+4.41%+25.45%+66.28% 202B
+4.21%+2.65%+17.47%+71.11% 163B
Average +2.36%+5.75%+25.47%+43.82% 369.24B
Weighted average by Cap. +2.25%+5.53%+41.78%+83.00%

Financials

2026 *2027 *
Net sales 1.15M 1.01M 927K 864K 1.64M 110M 1.66M 11.13M 4.33M 54.01M 4.33M 4.24M 186M 6.68M 5.84M 5.36M 5M 9.48M 636M 9.63M 64.4M 25.04M 313M 25.06M 24.53M 1.08B
Net income -41.07M -35.91M -33M -30.76M -58.34M -3.91B -59.22M -396M -154M -1.92B -154M -151M -6.62B -28.73M -25.12M -23.08M -21.51M -40.81M -2.74B -41.43M -277M -108M -1.34B -108M -106M -4.63B
Net Debt - -
Logo SCYNEXIS, Inc.
SCYNEXIS, Inc. is a biotechnology company focused on developing therapies to address severe rare diseases. The Company's SCY-770 is being developed for the treatment of Autosomal Dominant Polycystic Kidney Disease (ADPKD) and has been granted Orphan Drug designation. Its proprietary antifungal platform, fungerps, includes BREXAFEMME (ibrexafungerp tablets), which has been licensed to GSK, and SCY-247, which is in clinical stages of development. Its SCY-770 is a novel, highly selective, direct AMP-activated protein kinase (AMPK) activator for the treatment of ADPKD, a genetic cause of end-stage renal failure. Its SCY-770 is designed to address many of the underlying drivers of ADPKD by reducing cyst growth and disease progression. The United States Food and Drug Administration (FDA) has approved BREXAFEMME (ibrexafungerp tablets) for treatment of patients with vulvovaginal candidiasis (VVC) and for the reduction in the incidence of recurrent vulvovaginal candidiasis (rVVC).
Employees
18
Date Price Change Volume
02/07/26 USD 4.430 +4.73% 222,014
01/07/26 USD 4.230 +3.93% 115,572
30/06/26 USD 4.070 +5.17% 128,799
29/06/26 USD 3.870 +0.52% 32,140
26/06/26 USD 3.850 +1.05% 49,109
Trader
Investor
-
Global
-
Quality
-
ESG MSCI
-
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
3
Last Close Price
4.430USD
Average target price
33.55USD
Spread / Average Target
+657.26%

Quarterly revenue - Rate of surprise

  1. Stock Market
  2. Stocks
  3. SCYX Stock